IRIS Ultimaster Cohort in the IRIS-DES Registry
IRISUltimaster
Evaluation of Effectiveness and Safety of Ultimaster® Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
1 other identifier
observational
1,000
1 country
15
Brief Summary
The purpose of this study is to evaluate the relative effectiveness and safety of Ultimaster stent compared to other drug eluting stents.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2016
Longer than P75 for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 21, 2016
CompletedFirst Posted
Study publicly available on registry
March 25, 2016
CompletedStudy Start
First participant enrolled
July 20, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 24, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
August 8, 2024
CompletedDecember 29, 2025
December 1, 2025
4 years
March 21, 2016
December 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Composite event
The number of events with the first occurrence of a composite event(death, non-fatal myocardial infarction, target vessel revascularization)
1year
Secondary Outcomes (10)
All death
5years
Cardiac death
5years
Myocardial infarction
5years
Composite event of death or myocardial infarction
5years
Composite event of cardiac death or myocardial infarction
5years
- +5 more secondary outcomes
Study Arms (1)
Ultimaster stent
Interventions
Eligibility Criteria
patients with Ultimaster stent
You may qualify if:
- Age 19 and more
- Intervention with Ultimaster stent
- Agreed with written informed consent form
You may not qualify if:
- Intervention with Ultimaster stent and other drug eluting stent at the same time
- Life expectancy of 1year and under
- Cardiac shock
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Duk-Woo Park, MDlead
- CardioVascular Research Foundation, Koreacollaborator
Study Sites (15)
Sejong General hospital
Bucheon-si, South Korea
Gangwon National Univ. Hospital
Chuncheon, South Korea
Daegu Catholic University Medical Center
Daegu, South Korea
Keimyung University Dongsan Medical Center
Daegu, South Korea
Gangneung Asan Hospital
Gangneung, South Korea
Inje University Ilsan Paik Hospital
Ilsan, South Korea
Kwangju Christian Hospital
Kwangju, South Korea
Pusan National University Hospital
Pusan, South Korea
Asan Medical Center
Seoul, South Korea
The Catholic Univ. of Korea Seoul St. Mary's hospital
Seoul, South Korea
The Catholic University of Korea St. Paul's Hospital
Seoul, South Korea
The Catholic University of Korea, Yeouido St. Mary's Hospital
Seoul, South Korea
The Catholic University of Korea St. Vincent's Hospital
Suwon, South Korea
Ulsan University Hospital
Ulsan, South Korea
Wonju Severance Christian Hospital
Wŏnju, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Sponsor-investigator
Study Record Dates
First Submitted
March 21, 2016
First Posted
March 25, 2016
Study Start
July 20, 2016
Primary Completion
July 24, 2020
Study Completion
August 8, 2024
Last Updated
December 29, 2025
Record last verified: 2025-12